Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.

Autor: Elghawy O; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Barsouk A; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Reed-Guy L; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Stalker M; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Sussman J; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Robinson K; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Kosteva J; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Singh A; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Cohen RB; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Langer C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Ciunci C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., D'Avella C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Sun L; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Marmarelis ME; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Aggarwal C; Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.. Electronic address: Charu.Aggarwal@pennmedicine.upenn.edu.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2024 Dec 13. Date of Electronic Publication: 2024 Dec 13.

Synchronous Primary Lung Cancers Containing Discrete Driver Mutations in a Never-Smoker: Case Report.

Autor: Davis A; Drexel University College of Medicine, Philadelphia, PA, USA., Jarrar S; University of Pennsylvania, Philadelphia, PA, USA., Ciunci C; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Publikováno v: Case reports in oncology [Case Rep Oncol] 2023 Nov 14; Vol. 16 (1), pp. 1384-1389. Date of Electronic Publication: 2023 Nov 14 (Print Publication: 2023).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.

Autor: Aggarwal C; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Maity AP; Department of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA., Bauml JM; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Long Q; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Aleman T; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Ciunci C; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., D'Avella C; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Volpe M; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Anderson E; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Jones LM; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Sun L; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Singh AP; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Marmarelis ME; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Cohen RB; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Langer CJ; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Amaravadi R; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.

Publikováno v: The oncologist [Oncologist] 2023 Jul 05; Vol. 28 (7), pp. 644-e564.

EP08.01-018 Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression

Autor: Friedes, C., Yegya-Raman, N., Aggarwal, C., Marmarelis, M., Cohen, R., Levin, W., Cengel, K., Ciunci, C., Kosteva, J., Singh, A., Robinson, K., Sun, L., D'Avella, C., Davis, C., Langer, C., Feigenberg, S.

Publikováno v: In Journal of Thoracic Oncology September 2022 17(9) Supplement:S345-S345